PHILADELPHIA – Researchers from the Perelman School of Medicine at the University of Pennsylvania have developed a vaccine using mRNA to protect against genital herpes. Tested on both mice and guinea pigs, the immunization led to “mostly sterilizing immunity” from the virus—the strongest type of immunity. The results of the study are published today in Science Immunology.
HSV-2 Vaccine Study and Results
In the study, researchers delivered the Penn-developed vaccine to 64 mice and then exposed them to genital herpes. After 28 days, 63 of the mice were found to have sterilizing immunity, meaning there was no trace of herpes infection or disease after the exposure. The one remaining mouse developed dormant infection without any prior genital disease. Similarly, 10 guinea pigs, which have responses to herpes infections that more closely resemble that of humans, were also given the vaccine and exposed to the virus. No animal developed genital lesions and only two showed any evidence that they became infected, but the infection was not in a form that animals could transmit the virus.
“We’re extremely encouraged by the substantial immunizing effect our vaccine had in these animal models,” said the study’s principal investigator Harvey Friedman, MD, a professor of Infectious Diseases. “Based on these results, it is our hope that this vaccine could be translated into human studies to test both the safety and efficacy of our approach.”
The Development of a Genital Herpes Vaccine Using Modified mRNA
Building on the approaches of many cutting-edge cancer and immunotherapy researchers, the Penn team filled their vaccine with specific messenger RNA (mRNA), which can create proteins necessary for a strong immune response. This vaccine stimulates three types of antibodies: one that blocks the herpes virus from entering cells, and two others that ensure the virus doesn’t “turn off” innate immune system protective functions. This approach differs from other herpes vaccines, which often only rely on blocking virus’s entry as the mode to attack the virus.
This vaccine was developed with funding from NIH and as part of a collaboration between Penn Medicine and BioNTech, entered into in October 2018, to research and develop mRNA vaccines for various infectious diseases.
Genital herpes, also called Herpes simplex virus type 2 or HSV-2, is the most common sexually-transmitted disease. Approximately 14 percent of Americans ages 14 to 59, and 11 percent of people in the same age range across the world, are infected. HSV-2 may lead to painful sores, which can spread to other areas of the body. The virus increases one’s risk of contracting HIV, and infected pregnant women may pass herpes onto their fetus, or more commonly, to their baby during delivery.
“Along with physical symptoms, HSV-2 takes an emotional toll,” said Friedman. “People worry over transmission of the disease, and it can certainly have a negative effect on intimate relationships.”
Since herpes is so widespread but also often undetected, as it is only visible during an outbreak, researchers say a successful vaccine would be invaluable to many adults across the world.
Additional Penn authors on the study include Sita Awasthi, Lauren M. Hook, Norbert Pardi, Fushan Wang, Arpita Myles, Michael P. Cancro, Gary H. Cohen, and Drew Weissman.
This work was funded by the National Institutes of Health (AI045008) and BioNTech SE.
Editor’s Note: Penn has licensed certain Penn-owned intellectual property to BioNTech for development and commercialization of mRNA vaccines for infectious diseases, including IP rights related to an HSV-2 mRNA vaccine. The labs of Drew Weissman, Harvey Friedman, and Gary H. Cohen received sponsored researcher funding from BioNTech for research and development of mRNA vaccines for certain infectious diseases. Penn and Penn inventors may be eligible to receive financial benefit if an HSV-2 vaccine is clinically developed and commercialized by BioNTech.
Penn Medicine is one of the world’s leading academic medical centers, dedicated to the related missions of medical education, biomedical research, and excellence in patient care. Penn Medicine consists of the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania (founded in 1765 as the nation’s first medical school) and the University of Pennsylvania Health System, which together form a $8.9 billion enterprise.
The Perelman School of Medicine has been ranked among the top medical schools in the United States for more than 20 years, according to U.S. News & World Report's survey of research-oriented medical schools. The School is consistently among the nation's top recipients of funding from the National Institutes of Health, with $496 million awarded in the 2020 fiscal year.
The University of Pennsylvania Health System’s patient care facilities include: the Hospital of the University of Pennsylvania and Penn Presbyterian Medical Center—which are recognized as one of the nation’s top “Honor Roll” hospitals by U.S. News & World Report—Chester County Hospital; Lancaster General Health; Penn Medicine Princeton Health; and Pennsylvania Hospital, the nation’s first hospital, founded in 1751. Additional facilities and enterprises include Good Shepherd Penn Partners, Penn Medicine at Home, Lancaster Behavioral Health Hospital, and Princeton House Behavioral Health, among others.
Penn Medicine is powered by a talented and dedicated workforce of more than 44,000 people. The organization also has alliances with top community health systems across both Southeastern Pennsylvania and Southern New Jersey, creating more options for patients no matter where they live.
Penn Medicine is committed to improving lives and health through a variety of community-based programs and activities. In fiscal year 2020, Penn Medicine provided more than $563 million to benefit our community.